-
FDA updates approval of pemigatinib for the treatment of relapsed or refractory myeloid/lymphoid tumors with FGFR1 rearrangement
Time of Update: 2022-09-08
Administer pemitinib until disease progression, intolerable toxicity, or until the patient is able to receive allo-HSCT .
Administer pemitinib until disease progression, intolerable toxicity, or until the patient is able to receive allo-HSCT .
-
【Nature】Can this new target make T cells more durable and powerful in the tumor war?
Time of Update: 2022-09-08
This article is original from Translational Medicine Network, please indicate the source for reprinting Author: TMZHIIntroduction: Tumors often exploit immunosuppressive factors in their tumor microen
-
The post-sigmoid sinus opens the window location of the hearing preservation significance when the acoustic neuroma is removed
Time of Update: 2022-09-08
According to the patient's preoperative and postoperative CT, the position of the posterior margin of the craniolar window is determined by starting at the bottom of the internal auditory tract and walking behind the labyrinth to reach the scales of the occipital bone (FLL); The correlation between the location of the open cranial window and the probability of exposure of the underlying canal was assessed using a logistic regression model.
-
NSR (IF=23) Chinese Academy of Sciences Shi Jianlin's team discovered the immune mechanism of using nanomedicine to treat colorectal cancer
Time of Update: 2022-09-08
Integrating innate and adaptive immune activation based on this TAB-promoted nanocatalytic immune drug has been found to exhibit excellent therapeutic efficacy in an orthotopic colorectal cancer model, demonstrating the utility of this comprehensive immune strategy in clinical tumor immunotherapy.
-
JAMA Sub-Journal: Comparison of efficacy and safety of first-line chemotherapy regimens for advanced neuroendocrine cancer!
Time of Update: 2022-09-08
*For medical professional reading reference only1 minute a day, give you professional "talks" in the tumor circle! (If you need the original text of the literature, you can add Xiaobian WeChat yxj_onc
-
The team at Southern Medical University developed a non-invasive radiography biomarker for NLR in the tumor immune microenvironment
Time of Update: 2022-09-08
In addition, multivariate Cox regression analysis adjusted for clinical pathology variables showed that radioomic imaging biomarkers remained an independent prognostic factor for disease-free survival and overall survival in each cohort.
-
New Targets, New Hopes - These drugs are "hot" at the 2022 WCLC conference!
Time of Update: 2022-09-08
A comprehensive analysis of 372-001 (EudraCT 2012-000148-8), demonstrating its efficacy in patients with ROS1 fusion-positive (ROS1-fp) NSCLC and central nervous system (CNS) activity, showed an objective response rate (ORR) of 67% (n=108/161; data cut-off date: May 1, 2019; median survival follow-up time: 15.
-
Explorer | open up the road: "special" is not alone, the first CACA urothelial cancer integrated diagnosis and treatment guide national tour was successfully held!
Time of Update: 2022-09-08
Session 1 – Strive for Excellence 2022 EDITION OF THE CACA Guidelines for Urinary Urothelial Carcinoma Drug Treatment Guide Professor Shen Yijun of the Affiliated Cancer Hospital of Fudan University shared that the second-line treatment of advanced UC is mainly based on immunotherapy drugs such as triprimumab, and targeted therapy, immunotherapy, antibody conjugated drugs (ADCs) have gradually risen strongly in the treatment, opening a new era of advanced UC therapy and contributing to improving the survival rate of patients.
-
Amgen KRAS Inhibitor Meets Primary Endpoint of First Randomized Controlled Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
Time of Update: 2022-09-08
▲If you have any business needs, please long press to scan the QR code above, or▎Edited by WuXi AppTec Content TeamToday, Amgen announced that its KRAS G12C inhibitor, Lumakras (sotorasib), met its primary endpoint in a Phase 3 clinical trial in patients with previously treated non-small cell lung cancer harboring a KRAS G12C mutation, compared with standard chemotherapy.
-
IMS 2022 expresses new oral drug Mezigdomide combined with dexamethasone and bortezomib/carfilzomib for the treatment of RRMM with promising prospects
Time of Update: 2022-09-08
The Phase I/II trial CC-92480-MM-002 (NCT03989414) is evaluating MEZI in combination with different treatment regimens in patients with relapsed and refractory multiple myeloma (RRMM), researchers reported at this year's IMS meeting.
-
Professor Ma Jun: Seliniso has emerged, and the treatment of multiple myeloma is effective!
Time of Update: 2022-09-08
Although survival rates in patients with multiple myeloma (MM) have improved unprecedentedly in recent years thanks to the advent of drugs such as proteasome inhibitors (PIs), immunomodulators (IMiDs)
-
Voice of China's novel third-generation EGFR-TKI SH-1028 in second-line therapy for EGFR T790M mutation-positive NSCLC
Time of Update: 2022-09-08
This issue bringsZhou CaicunThe professor's team recently published a phase II clinical study in JTO to explore the efficacy and safety of a novel third-generation EGFR TKI (SH-1028) in patients with EGFR T790M-positive mutant NSCLC .
-
Prof. Jianyong Li & Lugui Qiu: The joint program of otolizumab limited courses has brought about a new breakthrough in CLL treatment
Time of Update: 2022-09-08
Chronic lymphocytic leukemia (CLL) is a mature B lymphocyte clone proliferative tumor that primarily involves peripheral blood and bone marrow. In recent years, with the continuous introduction of new
-
Accurately grasping the timing of switching TKI therapy is the key to achieving long-term survival of ALK-positive lung cancer!
Time of Update: 2022-09-08
*For medical professional reading reference onlyTo standardize the use of sequential therapy, the timing of switching TKIs is a key pointALK fusions are currently among the top treatment targets for non-small cell lung cancer (NSCLC), mainly because tyrosine kinase inhibitor (TKI) targeted drugs have significantly prolonged the survival of ALK-positive patients after they entered the clinic.
-
Sirona Pharmaceuticals achieved 100% complete remission in Phase II clinical trials of its skin cancer siRNA drug, siRNA technology may usher in a golden decade?
Time of Update: 2022-09-08
References:1 Official website of each company——List of recent popular activities——▼August 31, new technology for membrane protein target development▼September 8, iPSC-derived cell drug development strategyAug. 31, 2022/eMedClub News/--SinoMed announced today that in a Phase II clinical trial of STP705 in the treatment of basal cell carcinoma (BCC) of the skin, the cohort received the 180μg dose level achieved a 100% complete response (CR), indicating that the feasibility of the treatment is very promising .
-
With a sharp armor and a decisive victory over thousands of "cases" | donatifonib helps PATIENTS WITH RAIR-DTC survive for a long time
Time of Update: 2022-09-07
After screening, the patients met the "multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of dornafenib tosylate tablets in the treatment of locally advanced/metastatic iodine-refractory differentiated thyroid cancer (RAIR-DTC)" (ZGDD3 study) conducted by Henan Provincial Cancer Hospital, and were enrolled in the clinical trial.
-
IMS 2022 Express MRD-Driven Instructive Value for Discontinuation of Maintenance Therapy in Multiple Myeloma
Time of Update: 2022-09-07
Edit: moly Reviewer: Quinta Typesetting: moly Execution: molyClick "Read the original text" to see more contentThis year's IMS Annual Meeting reported interim results from a phase II study evaluating MRD-negative status after discontinuation of maintenance therapy in patients who had been in persistent MRD-negative remission for >3 years .
-
Science Sub-Journal: Ouyang Bo's team reveals the molecular mechanism of cholesterol regulating PD-L1 stability
Time of Update: 2022-09-07
So, is there a direct link between high levels of cholesterol in tumor cells and highly expressed PD-L1, and does cholesterol play a regulatory role in PD-L1?Recently, the Ouyang Bo Research Group of the Center for Excellence in Molecular and Cell Science (Institute of Biochemistry and Cell Biology) of the Chinese Academy of Sciences published a research paper entitled Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs in the journal Science Advances online.
-
The precursors of cancer are hidden here...
Time of Update: 2022-09-07
This humble little project is serum protein electrophoresis detection, that is, the determination of the percentage of various proteins in the serum as a percentage of total proteins by electrophoresis, serum protein electrophoresis is an important method of screening M protein, and M protein positivity is the key clue to the early diagnosis of many malignant tumors, such as multiple myeloma, lymphoma and other malignant tumors.
-
Increased colorectal risk from ultra-processed foods? Right! But not exactly... The three largest cohorts in the United States with more than 200,000 people studied to tell you the truth!
Time of Update: 2022-09-07
Therefore, this study aimed to assess the overall relationship between hyperprocessed food consumption and colorectal cancer risk, as well as the relationship between anatomical sites in men and women who participated in three large prospective cohort studies.
